IN THE CLAIMS

1. (currently amended)A compound of formula I



(1)

wherein

R^1

(i) is $-C_{1-10}$-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted ~~by -OH, -SH, -NH$_2$, -NHC$_{1-6}$-alkyl, -N(C$_{1-6}$-alkyl)$_2$, -NHC$_{6-14}$-aryl, -N(C$_{6-14}$-aryl)$_2$, -N(C$_{1-6}$-alkyl)(C$_{6-14}$-aryl), -NO$_2$, -CN, -F, -Cl, -Br, -I, -O-C$_{1-6}$-alkyl, -O-C$_{6-14}$-aryl, -S-C$_{1-6}$-alkyl, -S-C$_{6-14}$-aryl, -SO$_3$H, -SO$_2$C$_{1-6}$-alkyl, -SO$_2$C$_{6-14}$-aryl, -OSO$_2$C$_{1-6}$-alkyl, -OSO$_2$C$_{6-14}$-aryl, -COOH, -(CO)C$_{1-5}$-alkyl, -COO-C$_{1-5}$-alkyl, -O(CO)C$_{1-5}$-alkyl, by~~ by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members ~~or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,~~

wherein ~~the C$_{6-14}$-aryl groups and~~ the carbocyclic ~~and heterocyclic~~ substituents in turn are substituted one or more times by -NO_2 and may optionally be substituted one or more times by -C_{1-6}-alkyl, -OH, -NH_2, -NHC$_{1-6}$-alkyl, -N(C$_{1-6}$-alkyl)$_2$, -NO_2, -CN, -F, -Cl, -Br, -I, -O-C$_{1-6}$-alkyl, -

S-C_{1-6}-alkyl, -SO_3H, -SO_2C_{1-6}-alkyl, -OSO_2C_{1-6}-alkyl, -COOH, -$(CO)C_{1-5}$-alkyl, -COO-C_{1-5}-alkyl or/and –$O(CO)C_{1-5}$-alkyl, and wherein the alkyl groups on the carbocyclic ~~and heterocyclic~~ substituents in turn may optionally be substituted one or more times by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H or/and –COOH, ~~or~~

~~(ii) is C_{2-10}-alkenyl, mono- or polyunsaturated, straight-chain or branched chain, optionally mono- or polysubstituted by –OH, –SH, NH_2, NHC_{1-6}-alkyl, $N(C_{1-6}$-alkyl$)_2$, NHC_{6-14}-aryl, $N(C_{6-14}$-aryl$)_2$, $N(C_{1-6}$-alkyl$)(C_{6-14}$-aryl$)$, NO_2, CN, F, Cl, Br, I, O-C_{1-6}-alkyl, O-C_{6-14}-aryl, S-C_{1-6}-alkyl, S-C_{6-14}-aryl, SO_3H, SO_2C_{1-6}-alkyl, SO_2C_{6-14}-aryl, OSO_2C_{1-6}-alkyl, OSO_2C_{6-14}-aryl, COOH, $(CO)C_{1-5}$-alkyl, COO-C_{1-5}-alkyl, $O(CO)C_{1-5}$-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms, which are preferably N, O and S,~~

~~wherein the C_{6-14}-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by C_{1-6}-alkyl, –OH, NH_2, NHC_{1-6}-alkyl, $N(C_{1-6}$-alkyl$)_2$, NO_2, CN, F, Cl, Br, I, O-C_{1-6}-alkyl, S-C_{1-6}-alkyl, SO_3H, SO_2C_{1-6}-alkyl, OSO_2C_{1-6}-alkyl, COOH, $(CO)C_{1-5}$-alkyl, COO-C_{1-5}-alkyl or/and $O(CO)C_{1-5}$-alkyl,~~

~~and wherein the alkyl groups on the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by –OH, –SH, NH_2, F, Cl, Br, I, SO_3H or/and COOH,~~

R^2 is hydrogen or –C_{1-3}-alkyl,

R^3, R^4 and R^5 ~~R4 and R5~~ are hydrogen or a hydroxyl group, wherein at least one of these substituents must be a hydroxyl group,

R^6 and R^7 may be identical or different and are hydrogen, -C_{1-6}-alkyl, -OH, -SH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3-C_{1-6}-alkyl, -COOH, -COO-C_{1-6}-alkyl, -O(CO)-C_{1-5}-alkyl, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -phenyl or –pyridyl, wherein the phenyl or pyridyl substituents in turn may optionally be substituted one or more times by -C_{1-3}-alkyl, -OH, -SH, -NH_2, -NHC_{1-3}-alkyl, -$N(C_{1-3}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -F, -Cl, -Br, -I, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl, or/and –O(CO)C_{1-3}-alkyl, and wherein the alkyl substituents in turn may optionally be substituted one or more times by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl or/and –O(CO)-C_{1-3}-alkyl,

or salts of the compounds of formula 1.

2. (previously presented) A compound as claimed in claim 1 having at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (previously presented) A compound as claimed in claim 1 wherein R^2 is hydrogen or a methyl group.

4. (previously presented) A compound as claimed in claim 1, wherein R^3 = -H, R^4 = H and R^5 = -OH.

5. (previously presented) A compound as claimed in claim 1, wherein at least one of R^6 and R^7 is a halogen atom.

6. (currently amended) A compound according to claim 1 selected from the group consisting of:

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-4-hydroxyindol-3-yl]glyoxylamide;~~

N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(3-nitrobenzyl)-indol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(2-nitrobenzyl)-indol-3-yl]glyoxylamide;

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-(7-hydroxy-1-isobutylindol-3-yl)glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-cyclopropyl-methyl-7-hydroxyindol-3-yl)glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(4-hydroxybenzyl)-indol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(4-fluorobenzyl)-7-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;~~

~~N-(1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-6-hydroxyindol-3-yl]glyoxylamide;~~

and physiologically tolerated salts thereof.

7. (canceled)

8. (currently amended) A process ~~for~~ comprising preparing a compound of claim 1 by ~~1, comprising~~ converting N-(pyridine-4-yl)-indol-3-ylglyoxylamides of formula 2



(2)

into the analogous N-(1-oxopyridin-4-yl)-indol-3-ylglyoxylamides of formula 1 by treatment with an oxidizing agent, and forming the compound by eliminating a protective group.

9. (currently amended) ~~The~~ A process as claimed in claim 8, said oxidizing agent is selected from the group consisting of a peracid and a peracetic acid.

10. (currently amended) A method of treating disorders in which inhibition of phosphodiesterase 4 is therapeutically beneficial comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to ~~of~~ claim 1 to treat the disorder.

11. (currently amended) A method of treating disorders associated with the effect of eosinophils comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the disorder.

12. (currently amended) A method of treating disorders associated with the effect of neutrophils comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the disorder.

13. (currently amended) A method of treating a hyperproliferative disorder comprising administering a therapeutically effective amount of a compound according to ~~of~~ claim 1 to a patient in need thereof to treat the hyperproliferative disorder.

14. (currently amended) A drug product comprising a compound of claim 1 and ~~a~~ at least one conventional physiologically tolerated carrier, diluent and excipient.

15. (currently amended) A process for producing a drug product comprising admixing a compound of claim 1 with ~~a~~ at least one conventional pharmaceutical carrier, diluent or excipient to form the drug product.

16. (currently amended) A pharmaceutical composition comprising a at least one compound according to claim 1 and at least one additional active pharmaceutical agent.

17. (previously presented) The process as claimed in claim 8, wherein said oxidizing agent is m-chloroperbenzoic acid.